Jason Bock describes CTMC’s development model, the cell and gene therapy field’s main bottleneck, and progress he believes deserves more attention.
Approach:
CTMC model: Bock says CTMC combines clinical insight, manufacturing, analytics, regulatory strategy, and biotech partnerships to advance therapies from translational research through clinical testing and toward scale.
Scalability: He argues that cell therapy products and processes should be designed for scale from the outset, using approaches such as closed systems, automation, robotics, integrated analytics, and process control.
Industry progress: Bock says cell therapies are becoming part of mainstream oncology practice and moving into earlier treatment lines in some indications.
Key Findings:
Bock identifies CTMC’s tenth cleared IND, developed with biotech and academic partners, as a professional milestone.
He reports that patients in some first-in-human programs supported by CTMC have achieved complete responses; the article provides no program-level data or response rates.
He cites Obsidian’s OBX-115 as an example of CTMC and MD Anderson supporting initial IND work and first-in-human clinical translation. He says Obsidian has raised more than $600 million since beginning its collaboration with CTMC.
Bock identifies commercial scalability—not a lack of innovation—as the field’s biggest bottleneck, citing manufacturing speed, cost, variability, labor, and reliable delivery.
He says cell therapies have become standard of care in several indications and are moving into earlier lines of treatment.
Interpretation:
The article presents Bock’s perspective that cell therapy development must pair clinical progress with manufacturing and operational scalability. The statements are an interviewee’s account, not a reported independent evaluation of CTMC or the cited programs.
Limitations:
The source is an interview and reflects Bock’s views.
The provided context ends mid-sentence during the discussion of earlier-line treatment.
No supporting study data, response rates, or detailed evidence for the industry-wide claims are included.
Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new results from the PANKU-Breast02 Study on a new dual-antibody drug conjugate, called izalontamab brengitecan (iza-bren), for metastatic triple-negative breast cancer.
